OTCMKTS:DTCFF Defence Therapeutics (DTCFF) Stock Price, News & Analysis $0.17 -0.01 (-3.21%) As of 11/18/2026 02:45 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Defence Therapeutics Stock (OTCMKTS:DTCFF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Defence Therapeutics alerts:Sign Up Key Stats Today's Range$0.17▼$0.1750-Day Range$0.17▼$0.3652-Week Range$0.17▼$0.76Volume1,200 shsAverage Volume9,556 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Defence Therapeutics Inc. is a Canadian biotechnology company developing cancer treatments based on its proprietary Accum technology. The platform is designed to improve the delivery of therapeutic molecules into cells, with the goal of enhancing the effectiveness of cancer vaccines and antibody-drug conjugates. The company’s research pipeline includes AccuTOX, an investigational cancer immunotherapy, as well as vaccine and antibody-drug conjugate programs. Defence Therapeutics is focused on research and development and does not have marketed therapies. Based in Canada, the company is led by Chief Executive Officer Sébastien Plouffe.AI Generated. May Contain Errors. Read More Receive DTCFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Defence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DTCFF Stock News HeadlinesDefence Therapeutics Inc.: Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug ConjugatesOctober 1, 2026 | finanznachrichten.deDefence Therapeutics Inc.: Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of DirectorsSeptember 29, 2026 | finanznachrichten.deYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars. | Behind the Markets (Ad)Defence Therapeutics nomina Sherry Aulin nel consiglio di amministrazioneSeptember 29, 2026 | it.investing.comDefence Therapeutics : Provides Updates on Sharing AgreementSeptember 29, 2026 | marketscreener.comMDefence Therapeutics Inc.: Defence Therapeutics Provides Corporate Update as Company Executes on Strategic PrioritiesSeptember 28, 2026 | finanznachrichten.deDefence Therapeutics Inc.: Defence Therapeutics Provides Updates on Sharing AgreementSeptember 4, 2026 | finanznachrichten.deDefence Therapeutics Inc.: Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of ...August 17, 2026 | finanznachrichten.deSee More Headlines DTCFF Stock Analysis - Frequently Asked Questions How have DTCFF shares performed this year? Defence Therapeutics' stock was trading at $0.5576 at the start of the year. Since then, DTCFF stock has decreased by 68.7% and is now trading at $0.1748. How do I buy shares of Defence Therapeutics? Shares of DTCFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:DTCFF CIKN/A Webdefencetherapeutics.com Phone514 947 2272FaxN/AEmployees1,300Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (OTCMKTS:DTCFF) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour secret “Black Friday” link for tradersMarkham Trading's complete Alpha Oracle Signal system is just $7 for Black Friday. Others paid nearly $2,000 f...TradeWins | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Defence Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Defence Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.